Amgen meets key goals for Lumakras in late-stage lung cancer trial
Amgen (AMGN) announced Tuesday that the company’s KRAS G12C inhibitor Lumakras met the primary endpoint over standard of care chemotherapy with statistical significance in a…
Amgen meets key goals for Lumakras in late-stage lung cancer trial
Amgen (AMGN) announced Tuesday that the company’s KRAS G12C inhibitor Lumakras met the primary endpoint over standard of care chemotherapy with statistical significance in a…